Chris Polman

White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis

Wiebenga, O. T., Schoonheim, M. M., Hulst, H. E., Nagtegaal, G. J. A., Strijbis, E. M. M., Steenwijk, M. D., Polman, C. H., Pouwels, P. J. W., Barkhof, F. & Geurts, J. J. G., Jun 2016, In: American journal of neuroradiology. 37, 6, p. 1030-1037

Research output: Contribution to journal › Article › Academic › peer-review

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

Kuhle, J., Hardmeier, M., Disanto, G., Gugleta, K., Ecsedi, M., Lienert, C., Amato, M. P., Baum, K., Buttmann, M., Bayas, A., Brassat, D., Brochet, B., Confavreux, C., Edan, G., Färkkilä, M., Fredrikson, S., Frontoni, M., D'Hooghe, M., Hutchinson, M., De Keyser, J., & 9 othersKieseier, B. C., Kümpfel, T., Rio, J., Polman, C., Roullet, E., Stolz, C., Vass, K., Wandinger, K. P. & Kappos, L., 1 Apr 2016, In: MULTIPLE SCLEROSIS. 22, 4, p. 533-543 11 p.

Research output: Contribution to journal › Article › Academic › peer-review

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial

INFORMS study investigator group, 12 Mar 2016, In: Lancet. 387, 10023, p. 1075-1084 10 p.

Research output: Contribution to journal › Article › Academic › peer-review